Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF +2.57%49 Revenue per Share is $0.03 as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Abingdon Health ranks better than 94.76% on this metric.
Abingdon Health's revenue per share for the
six
months ended in Dec. 2025 was $0.01.
Abingdon Health's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.
Warning Sign:
Abingdon Health PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Abingdon Health was 19.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 32.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -16.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Abingdon Health's Revenue per Share or its related term are showing as below:
ABDXF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -38.2 Med: -24.2 Max: 32
Current: 32
During the past 8 years, Abingdon Health's highest 3-Year average Revenue Per Share Growth Rate was 32.00% per year. The lowest was -38.20% per year. And the median was -24.20% per year.
ABDXF's 3-Year Revenue Growth Rate is ranked better than 94.76% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.5
vs ABDXF: 32.00
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Abingdon Health Revenue per Share Related Terms
Abingdon Health Revenue per Share Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Abingdon Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Abingdon Health's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Abingdon Health's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Revenue per Share of $0.03 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Abingdon Health and its competitors. According to the industry distribution chart, Abingdon Health ranks #10 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 5.2%.
Is Abingdon Health's Revenue per Share too high?
Abingdon Health's current Revenue per Share is $0.03. The Medical Diagnostics & Research industry median Revenue per Share is 1.50. Abingdon Health's value of $0.03 is 98% below this industry median. Based on the distribution chart, Abingdon Health ranks #10 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Revenue per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #10 out of 191 companies for Revenue per Share. This places Abingdon Health in the top 5% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 1.50. Abingdon Health's value of $0.03 is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.50, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Revenue per Share of $0.03 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Revenue per Share is $0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 31.6% below its estimated fair value. The current Revenue per Share is $0.03 and 98% below the Medical Diagnostics & Research industry median of 1.50. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Revenue per Share is $0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 31.6% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
Revenue per Share: $0.03
GF Value™: $0.21 vs. price of $0.14 (31.6% below fair value)
Industry Position: 98% below the Medical Diagnostics & Research median (#10 of 191)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
